Individualized Treatment of Gastric cancer: Impact of Molecular Biology and Pathohistological Ueatures

World Journal of Gastrointestinal Oncology

Volumn 7, Issue 11, 2015, Pages 292-302

  Dittmar, Yves ^a   Settmacher, Utz ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Gastric cancer; Molecular biology; Personalized medicine; Signaling pathway; Targeted therapy

Indexed keywords

EID: 84992376923     PISSN: None     EISSN: 19485204     Source Type: Journal    
DOI: 10.4251/wjgo.v7.i11.292     Document Type: Article

References (81)

1. 1 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855]
2. 2 Meyer L, Steinert R, Nowak L, Gellert K, Ludwig K, Saeger D, Gastinger I, Lippert H. [Prospective multicenter trial of gastric cancer surgery—a contribution to clinical research on quality control]. Zentralbl Chir 2005; 130: 97-105 [PMID: 15849650]
3. 3 Cunningham SC, Schulick RD. Palliative management of gastric cancer. Surg Oncol 2007; 16: 267-275 [PMID: 17881220]
4. 4 Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 2002; 29: 3-14 [PMID: 11894009]
5. 5 Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232 [PMID: 7612182]
6. 6 Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N, Ooi A. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 2006; 118: 1173-1180 [PMID: 16161046]
7. 7 Gibault L, Metges JP, Conan-Charlet V, Lozac'h P, Robaszkiewicz M, Bessaguet C, Lagarde N, Volant A. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer 2005; 93: 107-115 [PMID: 15986037]
8. 8 Ruschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard MP, Penault-Llorca F, Nagelmeier I, Schlake W, Hofler H, Kreipe HH. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010; 457: 299-307 [PMID: 20665045]
9. 9 Ruschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G. HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012; 25: 637-650 [PMID: 22222640]
10. 10 Ayyappan S, Prabhakar D, Sharma N. Epidermal growth factor receptor (EGFR)-targeted therapies in esophagogastric cancer. Anticancer Res 2013; 33: 4139-4155 [PMID: 24122977]
11. 11 Galizia G, Lieto E, Orditura M, Castellano P, Mura AL, Imperatore V, Pinto M, Zamboli A, De Vita F, Ferraraccio F. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 2007; 31: 1458-1468 [PMID: 17516110]
12. 12 Waksal HW. Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev 1999; 18: 427-436 [PMID: 10855786]
13. 13 Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765 [PMID: 18946061]
14. 14 Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-28 [PMID: 19897418]
15. 15 Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, Baselga J. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25: 2171-2177 [PMID: 17538161]
16. 16 Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, Moehler M, Grabowski P, Arnold D, Greten T, Muller L, Rothling N, Peschel C, Langer R, Lordick F. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2009; 20: 1667-1673 [PMID: 19549707]
17. 17 Sch0nnemann KR, Yilmaz M, Bjerregaard JK, Nielsen KM, Pfeiffer P. Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum- resistant gastro-oesophageal cancer. Eur J Cancer 2012; 48: 510-517 [PMID: 22244801]
18. 18 Chan JA, Blaszkowsky LS, Enzinger PC, Ryan DP, Abrams TA, Zhu AX, Temel JS, Schrag D, Bhargava P, Meyerhardt JA, Wolpin BM, Fidias P, Zheng H, Florio S, Regan E, Fuchs CS. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol 2011; 22: 1367-1373 [PMID: 21217058]
19. 19 Lee MS, Mamon HJ, Hong TS, Choi NC, Fidias PM, Kwak EL, Meyerhardt JA, Ryan DP, Bueno R, Donahue DM, Jaklitsch MT, Lanuti M, Rattner DW, Fuchs CS, Enzinger PC. Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer. Oncologist 2013; 18: 281-287 [PMID: 23429739]
20. 20 Ruhstaller T, Pless M, Dietrich D, Kranzbuehler H, von Moos R, Moosmann P, Montemurro M, Schneider PM, Rauch D, Gautschi O, Mingrone W, Widmer L, Inauen R, Brauchli P, Hess V. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). J Clin Oncol 2011; 29: 626-631 [PMID: 21205757]
21. 21 Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6: 443-446 [PMID: 10742152]
22. 22 Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6: 117-127 [PMID: 15324695]
23. 23 Lane HA, Motoyama AB, Beuvink I, Hynes NE. Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. Ann Oncol 2001; 12 Suppl 1: S21-S22 [PMID: 11521716]
24. 24 Klos KS, Zhou X, Lee S, Zhang L, Yang W, Nagata Y, Yu D. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 2003; 98: 1377-1385 [PMID: 14508823]
25. 25 Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sanchez Rovira P, Piccart-Gebhart MJ. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369: 29-36 [PMID: 17208639]
26. 26 Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang Y-K, To GATI, Parnis F, McKendrick J, Price T, Mainwaring P, Van Cutsem E, Forones N, Olivatto L, Miziara JE, Li J, Wang J, Wang Y, Zheng L, Wang L, Feng-Yi F, Shen L, Xu JM, Jiao S, Guan Z, Yu SY, Pan L, Jin Y, Tao M, Qin S, Reyes DO, Valladares R, Landaverde D, Pfeiffer P, Vestlev PM, Tanner M, Bouche O, Michel P, Jacob J, Husseini F, Metges JP, Dominguez S, Viret F, Clemens M, zum Buschenfelde COM, Moehler M, Hoefeler H, Lordick F, Toache LMZ, Castro- Salguero H, Prasad SVSS, Gangadharan VP, Advani S, Julka PK, Aprile G, Barone C, Cascinu S, Di Costanzo F, Stefania S, Hamamoto Y, Sasaki Y, Yamaguchi K, Ohtsu A, Hatake K, Satoh A, Boku N, Sawaki A, Takiuchi H, Tamura T, Baba E, Nishina T, Miyata Y, Satoh T, Omuro Y, Saito H, Bang YJ, Kang YK, Hong DS, Jeung HC, Lim HY, Chung HC, Kim JG, Kim YH, Lee K, Park S, Leon E, Trevino SA, Sahui TS, Rodriguez AL, Sanchez RIL, Alvarez-Barreda R, de Mendoza FH, Leon-Chong J, Philco M, Sanches E, Quintela A, Sa A, Damasceno M, Coutinho C, Pinto AM, Teixeira MM, Braga S, Topuzov E, Cheporov S, Garin A, Gorbunova V, Lichinitser M, Khasanov RS, Manikhas GM, Biakhov M, Moiseenko V, Gotovkin E, Kulikov E, Lipatov O, Gladkov O, Landers G, Robertson B, Gravalos C, Queralt B, Galan MC, Gallego R, Aguilera MJS, Martin M, Fernandez-Martos C, Chao Y, Chang C, Yalcin S, Yilmaz U, Evans J, Falk S, Mansoor W, Ferry D, Thompson J, Gollins S. Trastuzumab in combination with chemotherapy vs chemotherapy alone for treatment of HER2- positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697 [PMID: 20728210]
27. 27 Barok M, Tanner M, Koninki K, Isola J. Trastuzumab-DMI is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett 2011; 306: 171-179 [PMID: 21458915]
28. 28 Hamano S, Mori Y, Aoyama M, Kataoka H, Tanaka M, Ebi M, Kubota E, Mizoshita T, Tanida S, Johnston RN, Asai K, Joh T. Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells. Cancer Lett 2015; 356: 846-854 [PMID: 25444894]
29. 29 Rao S, Starling N, Cunningham D, Sumpter K, Gilligan D, Ruhstaller T, Valladares-Ayerbes M, Wilke H, Archer C, Kurek R, Beadman C, Oates J. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Ann Oncol 2010; 21: 2213-2219 [PMID: 20497967]
30. 30 Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, Ferry D, Mansoor W, Crosby T, Coxon F, Smith D, Waters J, Iveson T, Falk S, Slater S, Peckitt C, Barbachano Y. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 14: 481-489 [PMID: 23594787]
31. 31 Dawood S, Sirohi B. Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer. Future Oncol 2015; 11: 923-931 [PMID: 25760974]
32. 32 Kang YK, Rha SY, Tassone P, Barriuso J, Yu R, Szado T, Garg A, Bang YJ. A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. Br J Cancer 2014; 111: 660-666 [PMID: 24960402]
33. 33 Sullivan LA, Brekken RA. The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs 2010; 2: 165-175 [PMID: 20190566]
34. 34 Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358: 2039-2049 [PMID: 18463380]
35. 35 Fontanella C, Ongaro E, Bolzonello S, Guardascione M, Fasola G, Aprile G. Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med 2014; 2: 123 [PMID: 25568876]
36. 36 Ebos JM, Bocci G, Man S, Thorpe PE, Hicklin DJ, Zhou D, Jia X, Kerbel RS. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res 2004; 2: 315-326 [PMID: 15235107]
37. 37 Aprile G, Bonotto M, Ongaro E, Pozzo C, Giuliani F. Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use. Drugs 2013; 73: 2003-2015 [PMID: 24277700]
38. 38 Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana CD, Ellis LM. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res 1996; 2: 1679-1684 [PMID: 9816116]
39. 39 Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. Bevacizumab in combination with chemotherapy as first- line therapy in advanced gastric cancer: a randomized, double¬blind, placebo-controlled phase III study. J Clin Oncol 2011; 29: 3968-3976 [PMID: 21844504]
40. 40 Shen L, Li J, Xu J, Pan H, Dai G, Qin S, Wang L, Wang J, Yang Z, Shu Y, Xu R, Chen L, Liu Y, Yu S, Bu L, Piao Y. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer 2015; 18: 168-176 [PMID: 24557418]
41. 41 Miao HQ, Hu K, Jimenez X, Navarro E, Zhang H, Lu D, Ludwig DL, Balderes P, Zhu Z. Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2. Biochem Biophys Res Commun 2006; 345: 438-445 [PMID: 16682007]
42. 42 Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J, Investigators RT, Mendez G, Maldonado D, Bartoli M, Guminski A, Ransom D, Price T, Jefford M, Karapetis C, Zalcberg J, Young R, Eek R, Beslija S, Barrios C, Franke F, Brust L, Murad A, Andrade A, Nascimento Y, Liberatti M, Azambuja A, Skare NS, Schwartsmann G, Vieira dos Santos L, Lunardon Padilha S, Alberto Schlittler L, Spratlin J, Tehfe M, del Castillo C, Enrique Gonzalez Fernandez M, Bilic A, Mihaljevic S, Boric Z, Trivanovic D, Stahalova V, Brychta M, Vanasek J, Jakesova J, Lazarov P, Petera J, Zemanova M, Deeb N, Avendano Flores O, Chakravarthy S, Dassappa L, Ramanan S, Deshmukh C, Sivanandan C, Almel S, Kumar R, Prayogo N, Rudiman R, Bilancia D, Ravaioli A, Frustaci S, Bari M, Amoroso V, Amoroso D, Martoni A, Kim Y-H, Hong YS, Chung H, Cho Cho JY, Chehade I, Brincat S, Gibbs D, Querol J, Koralewski P, Rozamowski P, Ganea-Motan D, Filip D, Udrea A, Gorbunova V, Protsenko S, Gladkov O, Vladimirov V, Severtsev A, Akopov A, Orlov S, Robertson B, Fernandez Parra E, Rivera Herrero F, Longo F, Visa L, Hurtado A, Gallego Plazas J, Wang J-Y, Kok V, Thongprasert S, Erkisi M, Sevinc A, Turhal S, Gokmen E, Smith D, Ferry D, Hanna W, Leslie W, Barnhill M, Thomas M, Cescon T, Langdon R, Patel R, Kozuch P, Ajani J, Reid T, Malik I, Gravenor D, Fuchs C. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383: 31-39 [PMID: 24094768]
43. 43 Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014; 15: 1224-1235 [PMID: 25240821]
44. 44 Heldin CH. Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal 2013; 11: 97 [PMID: 24359404]
45. 45 Li X, Eriksson U. Novel PDGF family members: PDGF-C and PDGF-D. Cytokine Growth Factor Rev 2003; 14: 91-98 [PMID: 12651221]
46. 46 Suzuki S, Dobashi Y, Hatakeyama Y, Tajiri R, Fujimura T, Heldin CH, Ooi A. Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-p phosphorylation, and microvessel density in gastric cancer. BMC Cancer 2010; 10: 659 [PMID: 21118571]
47. 47 Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med Res Rev 2014; 34: 280-300 [PMID: 23696246]
48. 48 Hattori Y, Itoh H, Uchino S, Hosokawa K, Ochiai A, Ino Y, Ishii H, Sakamoto H, Yamaguchi N, Yanagihara K, Hirohashi S, Sugimura T, Terada M. Immunohistochemical detection of K-sam protein in stomach cancer. Clin Cancer Res 1996; 2: 1373-1381 [PMID: 9816310]
49. 49 Chmielowiec J, Borowiak M, Morkel M, Stradal T, Munz B, Werner S, Wehland J, Birchmeier C, Birchmeier W. c-Met is essential for wound healing in the skin. J Cell Biol 2007; 177: 151-162 [PMID: 17403932]
50. 50 Huh CG, Factor VM, Sanchez A, Uchida K, Conner EA, Thorgeirsson SS. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci USA 2004; 101: 4477-4482 [PMID: 15070743]
51. 51 Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012; 12: 89-103 [PMID: 22270953]
52. 52 Smyth EC, Sclafani F, Cunningham D. Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth¬factor inhibitors. Onco Targets Ther 2014; 7: 1001-1014 [PMID: 24959087]
53. 53 Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, Tahara E. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 1992; 189: 227-232 [PMID: 1333188]
54. 54 Iveson T, Donehower RC, Davidenko I, Tjulandin S, Deptala A, Harrison M, Nirni S, Lakshmaiah K, Thomas A, Jiang Y, Zhu M, Tang R, Anderson A, Dubey S, Oliner KS, Loh E. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double¬blind, randomised phase 2 study. Lancet Oncol 2014; 15: 1007-1018 [PMID: 24965569]
55. 55 Caruso R, Pallone F, Fina D, Gioia V, Peluso I, Caprioli F, Stolfi C, Perfetti A, Spagnoli LG, Palmieri G, Macdonald TT, Monteleone G. Protease-activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor receptor trans-activation and proliferation. Am J Pathol 2006; 169: 268-278 [PMID: 16816379]
56. 56 Yang L, Xie G, Fan Q, Xie J. Activation of the hedgehog-signaling pathway in human cancer and the clinical implications. Oncogene 2010; 29: 469-481 [PMID: 19935712]
57. 57 Kim EJ, Sahai V, Abel EV, Griffith KA, Greenson JK, Takebe N, Khan GN, Blau JL, Craig R, Balis UG, Zalupski MM, Simeone DM. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res 2014; 20: 5937-5945 [PMID: 25278454]
58. 58 Meiss F, Zeiser R. Vismodegib. Recent Results Cancer Res 2014; 201: 405-417 [PMID: 24756807]
59. 59 Katoh Y, Katoh M. Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr Mol Med 2009; 9: 873-886 [PMID: 19860666]
60. 60 Hu T, Li C. Convergence between Wnt-p-catenin and EGFR signaling in cancer. Mol Cancer 2010; 9: 236 [PMID: 20828404]
61. 61 Takada R, Satomi Y, Kurata T, Ueno N, Norioka S, Kondoh H, Takao T, Takada S. Monounsaturated fatty acid modification of Wnt protein: its role in Wnt secretion. Dev Cell 2006; 11: 791-801 [PMID: 17141155]
62. 62 Wu WK, Cho CH, Lee CW, Fan D, Wu K, Yu J, Sung JJ. Dysre- gulation of cellular signaling in gastric cancer. Cancer Lett 2010; 295: 144-153 [PMID: 20488613]
63. 63 Tahara E. Molecular biology of gastric cancer. World J Surg 1995; 19: 484-488; discussion 489-490 [PMID: 7676688]
64. 64 Borggrefe T, Oswald F. The Notch signaling pathway: transcriptional regulation at Notch target genes. Cell Mol Life Sci 2009; 66: 1631-1646 [PMID: 19165418]
65. 65 Ronchini C, Capobianco AJ. Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic). Mol Cell Biol 2001; 21: 5925-5934 [PMID: 11486031]
66. 66 Du X, Cheng Z, Wang YH, Guo ZH, Zhang SQ, Hu JK, Zhou ZG. Role of Notch signaling pathway in gastric cancer: a meta-analysis of the literature. World J Gastroenterol 2014; 20: 9191-9199 [PMID: 25083094]
67. 67 Mishra L, Derynck R, Mishra B. Transforming growth factor-beta signaling in stem cells and cancer. Science 2005; 310: 68-71 [PMID: 16210527]
68. 68 Miyazono K, Suzuki H, Imamura T. Regulation of TGF-beta signaling and its roles in progression of tumors. Cancer Sci 2003; 94: 230-234 [PMID: 12824914]
69. 69 Kim YI, Lee HJ, Khang I, Cho BN, Lee HK. Selective inhibition of cell growth by activin in SNU-16 cells. World J Gastroenterol 2006; 12: 3000-3005 [PMID: 16718778]
70. 70 Gupta S, Gill D, Pal SK, Agarwal N. Activin receptor inhibitors— dalantercept. Curr Oncol Rep 2015; 17: 14 [PMID: 25708802]
71. 71 O'Connor PM. Mammalian G1 and G2 phase checkpoints. Cancer Surv 1997; 29: 151-182 [PMID: 9338101]
72. 72 Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 2005; 23: 9408-9421 [PMID: 16361640]
73. 73 Boonstra J. Progression through the G1-phase of the on-going cell cycle. J Cell Biochem 2003; 90: 244-252 [PMID: 14505341]
74. 74 Akama Y, Yasui W, Yokozaki H, Kuniyasu H, Kitahara K, Ishikawa T, Tahara E. Frequent amplification of the cyclin E gene in human gastric carcinomas. Jpn J Cancer Res 1995; 86: 617-621 [PMID: 7559076]
75. 75 Yasui W, Akama Y, Kuniyasu H, Yokozaki H, Semba S, Shimamoto F, Tahara E. Expression of cyclin-dependent kinase inhibitor p21WAF1/CIP1 in non-neoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity. J Pathol 1996; 180: 122-128 [PMID: 8976868]
76. 76 Menendez D, Inga A, Resnick MA. The expanding universe of p53 targets. Nat Rev Cancer 2009; 9: 724-737 [PMID: 19776742]
77. 77 Fenoglio-Preiser CM, Wang J, Stemmermann GN, Noffsinger A. TP53 and gastric carcinoma: a review. Hum Mutat 2003; 21: 258-270 [PMID: 12619111]
78. 78 Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 2015; 14: 130-146 [PMID: 25633797]
79. 79 Whittaker SR, Te Poele RH, Chan F, Linardopoulos S, Walton MI, Garrett MD, Workman P. The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis. Cell Cycle 2007; 6: 3114-3131 [PMID: 18075315]
80. 80 Tong F, Cao P, Yin Y, Xia S, Lai R, Liu S. MicroRNAs in gastric cancer: from benchtop to bedside. Dig Dis Sci 2014; 59: 24-30 [PMID: 24114043]
81. 81 Kang C, Song JJ, Lee J, Kim MY. Epigenetics: an emerging player in gastric cancer. World J Gastroenterol 2014; 20: 6433-6447 [PMID: 24914365]